Differences between basal lung levels of select eicosanoids in rat and mouse

Pulmonary Circulation

Volumn 3, Issue 1, 2013, Pages 82-88

  Sagliani, Kristen D ^a   Dolnikowski, Gregory G ^b   Hill, Nicholas S ^a   Fanburg, Barry L ^a   Levy, Bruce D ^c   Preston, Ioana R ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Eicosanoids; LC MS MS; Lipoxygenase; Liquid chromatography; Prostacyclin; Prostaglandin; Pulmonary hypertension; Tandem mass spectrometry; Thromboxane

Indexed keywords

EID: 84977498944     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.109918     Document Type: Article

References (28)

1. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001;294:1871-5.
2. Casey LC, Fletcher JR, Zmudka MI, Ramwell PW. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. J Pharmacol Exp Ther 1982;222:441-6.
3. Dusting GJ, Moncada S, Vane JR. Prostaglandins, their intermediates and precursors: Cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. Prog Cardiovasc Dis 1979;21:405-30.
4. Preston IR, Hill NS, Warburton RR, Fanburg BL. Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 2006;290:L367-74.
5. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995;75:3A-10A.
6. Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R, et al. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 1995;26:771-80.
7. Rabinovitch M, Mullen M, Rosenberg HC, Maruyama K, O’Brodovich H, Olley PM. Angiotensin II prevents hypoxic pulmonary hypertension and vascular changes in rat. Am J Physiol 1988;254 (3 Pt 2):H500-8.
8. Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension. Chest 1998;114:205S-7S.
9. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
10. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
11. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
12. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-32.
13. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007;178:496-502.
14. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 2010;184:836-43.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
16. Yang R, Chiang N, Oh SF, Serhan CN. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol 2011;Chapter 14:Unit 14.26.
17. Ceserani R, Gandolfi C, Usardi MM, Bergamaschi M. PGE2:PGE-2: Prostaglandins 1975;9:97-107.
18. Jones JE, Walker JL, Song Y, Weiss N, Cardoso WV, Tuder RM, et al. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2004;286:H1775-84.
19. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61.
20. Li S, Ran Y, Zheng X, Pang X, Wang Z, Zhang R, et al. 15-HETE mediates sub-acute hypoxia-induced TRPC1 expression and enhanced capacitative calcium entry in rat distal pulmonary arterial myocytes. Prostaglandins Other Lipid Mediat 2010;93:60-74.
21. Zhu D, Medhora M, Campbell WB, Spitzbarth N, Baker JE, Jacobs ER. Chronic hypoxia activates lung 15-lipoxygenase, which catalyzes production of 15-HETE and enhances constriction in neonatal rabbit pulmonary arteries. Circ Res 2003;92:992-1000.
22. Nie X, Song S, Zhang L, Qiu Z, Shi S, Liu Y, et al. 15-Hydroxyeicosatetraenoic acid (15-HETE) protects pulmonary artery smooth muscle cells from apoptosis via inducible nitric oxide synthase (iNOS) pathway. Prostaglandins Other Lipid Mediat 2012;97:50-9.
23. Aggarwal NT, Chawengsub Y, Gauthier KM, Viita H, Yla-Herttuala S, Campbell WB. Endothelial 15-lipoxygenase-1 overexpression increases acetylcholine-induced hypotension and vasorelaxation in rabbits. Hypertension 2008;51:246-51.
24. Chawengsub Y, Aggarwal NT, Nithipatikom K, Gauthier KM, Anjaiah S, Hammock BD, et al. Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta. Am J Physiol Heart Circ Physiol 2008;294:H1348-56.
25. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
26. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103:1509-15.
27. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ 2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A 1992;89:10721-5.
28. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999;274:24441-4.